Enthera Pharmaceuticals Will Present Preclinical Data on Ent001, an Anti-TMEM219 Antibody in Development For The Treatment Of Ulcerative Colitis at The European Crohn’s And Colitis Organization 2024 Annual Meeting

Enthera Pharmaceuticals (“Enthera”), a clinical-stage biotech company developing first-in-class antibody therapeutics targeting the Insulin Growth Factor Binding Protein (IGFBP) family for selected inflammatory diseases, confirms its attendance at the European Crohn´s and Colitis Organization – ECCO’24 (ecco-ibd.eu) Conference, scheduled to take place in Stockholm from February 21st to 24th. Enthera will be presenting new preclinical […]

Enthera Pharmaceuticals Appoints Lisa M. Olson as CEO and Announces Clinical Trial Progress with Ent001

Industry veteran Dr. Olson moves from Enthera’s Board to take the helm as CEO Ent001 Phase 1a trial in healthy volunteers completed with positive topline safety results Company has initiated enrollment for Ent001 Phase 1b trial in patients with moderately to severely active ulcerative colitis Milan, Italy, January 23, 2024 – Enthera Pharmaceuticals (“Enthera”), a […]

Enthera Pharmaceuticals Initiates Phase 1 Clinical Trial with Lead Candidate Ent001

Phase 1 study in healthy volunteers lays groundwork for Ent001 evaluation in patients with inflammatory bowel disease and type 1 diabetes Milan, Italy, March 7, 2023 – Enthera Pharmaceuticals (“Enthera”), a biotech company developing first-in-class biologics for selected autoimmune conditions, today announces the start of a Phase 1 first-in-human (FIH) clinical trial with its lead […]